Sonoma Pharmaceuticals (NASDAQ:SNOA) Shares Cross Above 50-Day Moving Average – What’s Next?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) shares crossed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $1.21 and traded as high as $1.2990. Sonoma Pharmaceuticals shares last traded at $1.24, with a volume of 324,217 shares changing hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company has a consensus rating of “Sell”.

Sonoma Pharmaceuticals Stock Up 8.8%

The company has a market cap of $5.94 million, a P/E ratio of -1.36 and a beta of 1.31. The company has a fifty day moving average of $1.21 and a 200 day moving average of $1.64.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its earnings results on Tuesday, November 10th. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.19. The company had revenue of $7.17 million for the quarter, compared to the consensus estimate of $5.29 million. Sonoma Pharmaceuticals had a negative return on equity of 5.44% and a negative net margin of 7.65%.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing and commercializing non-antibiotic and non-steroidal products for human and animal health. Its products are designed for applications including dermatology, wound care, eye care and veterinary treatment. The company’s product portfolio is based primarily on Microcyn technology, a stabilized hypochlorous acid solution intended to cleanse, debride and manage wounds and various skin conditions. Products marketed under the company’s brands have included Dermacyn, for wound and skin care, and Ocucyn, for ophthalmic care, along with veterinary products and other prescription and over-the-counter formulations.